Novartis AG - Free Cash Flow To Equity

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Free-Cash-Flow-To-Equity" stands at 17.34 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Novartis AG's third quarter result of 5.23 Billion USD for the item "Free Cash Flow To Equity" represents a decrease of -16.83 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 5.23 Billion USD for the item "Free Cash Flow To Equity" represents a decrease of -34.61 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 17.34 Billion USD for the item "Free Cash Flow To Equity" represents a decrease of -13.77 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 11.26 Billion United States Dollars compared to the value the year prior.
The 1 year change is 11.26 Billion United States Dollars.
The 3 year change is 10.73 Billion United States Dollars.
The 5 year change is -0.599 Billion United States Dollars.

The Serie's long term average value is 2.23 Billion United States Dollars. It's latest available value, on 09/30/2025, is 15.11 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 06/30/2023, to it's latest available value, on 09/30/2025, is +29.57 Billion.
The Serie's change in United States Dollars from it's maximum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is -2.77 Billion.